Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland

British Journal of Cancer

Volumn 111, Issue 9, 2014, Pages 1824-1830

  Pollock, K G J ^a   Kavanagh, K ^b   Potts, A ^a   Love, J ^a   Cuschieri, K ^c   Cubie, H ^c   Robertson, C ^a   Cruickshank, M ^d   Palmer, T J ^e   Nicoll, S ^f   Donaghy, M ^a  

^a HEALTH PROTECTION SCOTLAND   (United Kingdom)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^d UNIVERSITY OF ABERDEEN   (United Kingdom)

^e RAIGMORE HOSPITAL   (United Kingdom)

^f NINEWELLS HOSPITAL   (United Kingdom)

Author keywords

cervical intraepithelial neoplasia; human papillomavirus; vaccine

Indexed keywords

WART VIRUS VACCINE; VACCINE;

ADULT; ARTICLE; CANCER DIAGNOSIS; COHORT ANALYSIS; COLPOSCOPY; COMPARATIVE STUDY; DISEASE SURVEILLANCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; UNITED KINGDOM; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; CANCER GRADING; CERVICAL INTRAEPITHELIAL NEOPLASIA; EPIDEMIOLOGY; FOLLOW UP; ISOLATION AND PURIFICATION; MASS SCREENING; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; PREVALENCE; PROGNOSIS; PUBLIC HEALTH; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS; VAGINA SMEAR; VIROLOGY; YOUNG ADULT;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; COHORT STUDIES; COLPOSCOPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MASS SCREENING; NATIONAL HEALTH PROGRAMS; NEOPLASM GRADING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; PROGNOSIS; SCOTLAND; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS; VACCINATION; VACCINE POTENCY; VAGINAL SMEARS; YOUNG ADULT;

EID: 84908497852     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.479     Document Type: Article

References (27)

1. Baker D, Middleton E (2003) Cervical screening and health inequality in England in the 1990s. J Epidemiol Community Health 57: 417-423.
2. Baldur-Felskov B, Dehlendorff C, Munk C, Kjaer SK (2014) Early impact of human papillomavirus vaccination on cervical neoplasia-nationwide follow-up of young Danish women. J Natl Cancer Inst 106: Djt460.
3. Bhopal RS, Bansal N, Steiner M, Brewster DH. Scottish Health and Ethnicity Linkage Study (2012) Does the 'Scottish effect' apply to all ethnic groups?. All-cancer, lung, colorectal, breast and prostate cancer in the Scottish Health and Ethnicity Linkage Cohort Study. BMJ Open 2: Pii: E001957.
4. Bowyer HL, Marlow LA, Hibbitts S, Pollock KG, Waller J (2013) Knowledge and awareness of HPV and the HPV vaccine among young women in the first routinely vaccinated cohort in England. Vaccine 31: 1051-1056.
5. Brotherton JML, FridmanM, MayCL, ChappellG, SavilleAM, GertigDM(2011) Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: An ecological study. Lancet 377: 2085-2092.
6. Cancer research UK (2010) London: Cancer Research UK. Cervical cancer-UK incidence statistics http://info.cancerresearchuk.org/cancerstats/types/cervix/incidence/. Accessed 07 February 2014.
7. Crowe E, Pandeya N, Brotherton JM, Dobson AJ, Kisely S, Lambert SB, Whiteman DC (2014) Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: Case-control study nested within a population based screening programme in Australia. BMJ Open 348: G1458.
8. Cuschieri K, Brewster DH, Williams ARW, Millan D, Murray G, Nicoll S, Imrie J, Hardie A, Graham C, Cubie HA (2010) Distribution of HPV types associated with cervical cancers in Scotland and implications for the impact of HPV vaccines. Br J Cancer 102: 930-932.
9. Henderson L, Clements A, Damery S, Wilkinson C, Austoker J, Wilson S. HPV Core Messages Writing Group (2011) 'A false sense of security'?. Understanding the role of the HPV vaccine on future cervical screening behaviour: A qualitative study of UK parents and girls of vaccination age. J Med Screen 18: 41-45.
10. Hopkins TG, Wood N (2013) Female human papillomavirus (HPV) vaccination: Global uptake and the impact of attitudes. Vaccine 31: 1673-1679.
11. Information Services Division, Scotland (2011) Estimate of HPV vaccine uptake in Scotland by year of birth http://www.isdscotland.org/Health-Topics/Child-Health/Publications/2011-09-22/HPV-by-YOB-Aug11. xls. Accessed 07 February 2014.
12. Information Services Division, Scotland (2012) Estimate of HPV vaccine uptake in Scotland by year of birth, catch-up cohort http://www. isdscotland.org/Health-Topics/Child-Health/Publications/2012-09-25/HPV-Catch-up-Programme.xlsAccessed 07 February 2014.
13. Kavanagh K, Pollock KGJ, Potts A, Love J, Cuschieri K, Cubie H, Robertson C, Donaghy M (2014) Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer 110: 2804-2811.
14. Kavanagh K, Sinka K, Cuschieri K, Love J, Potts A, Pollock KG, Cubie H, Donaghy M, Robertson C (2013) Estimation of HPV prevalence in young women in Scotland; monitoring of future vaccine impact. BMC Infect Dis 13: 519.
15. Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, Gonzalez P, Solomon D, Jimenez S, Schiller JT, Lowy DR, Quint W, Sherman ME, Schussler J, Wacholder S. CVT Vaccine Group (2011) Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 103: 1444-1451.
16. Malagon T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, Brisson M (2012) Cross-protective efficacy of two human papillomavirus vaccines: A systematic review and meta-Analysis. Lancet Infect Dis 12: 781-789.
17. Marlow LAV, Waller J, Wardle J (2007) Public awareness that HPV is a risk factor for cervical cancer. Br J Cancer 97: 691-694.
18. O'Leary MC, Sinka K, Robertson C, Cuschieri K, Lyman R, Lacey M, Potts A, Cubie HA, Donaghy M (2011) HPV type-specific prevalence using a urine assay in unvaccinated male and female 11-To 18-year olds in Scotland. Br J Cancer 104: 1221-1226.
19. Paavonen J, Naud P, Salmeron J,Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G (2009) Efficacy of human papillomavirus (HPV)-16/18 AS04-Adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. Lancet 374: 301-314.
20. Powell SE, Hariri S, Steinau M, Bauer HM, Bennett NM, Bloch KC, Niccolai LM, Schafer S, Unger ER, Markowitz LE (2012) Impact of human papillomavirus (HPV) 16/18-related prevalence in precancerous cervical lesions. Vaccine 31: 109-113.
21. R Development Core Team (2014) R: A Language and Environment for Statistical computing. R Foundation for Statistical Computing: Vienna, Austria, ISBN 3-900051-07-0, URL http://www.R-project.org/.
22. Romanowski B, Schwarz TF, Ferguson LM, Peters K, Dionne M, Schulze K, Ramjattan B, Hillemanns P, Catteau G, Dobbelaere K, Schuind A, Descamps D (2011) Immunogenicity and safety of the HPV-16/18 AS04-Adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: Results from a randomized study. Hum Vaccin 7: 1374-1386.
23. Scottish Government (2005) Scottish Neighbourhood Statistics Guide. http://www.scotland.gov.uk/Publications/2005/02/20697/52626. Accessed online 07 February 2014.
24. Scottish Government. Scottish Index of Multiple Deprivation http://www. scotland.gov.uk/Topics/Statistics/SIMD. Accessed online 07 February 2014.
25. Sinka K, Kavanagh K, Gordon R, Love J, Potts A, Donaghy M, Robertson C (2014) Introduction, high and equitable coverage of adolescent HPV vaccine in Scotland. J Epidemiol Community Health 68: 57-63.
26. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM (2007) Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-Analysis update. Int J Cancer 21: 621-632.
27. Wheeler CM, Castellsaque X, Garland SM, Szarewski A, Paavonen J, Naud P, Salmeron J, Chow SN, Apter D, Kitchener H, Teixeira JC, Skinner SR, Jaisamrarn U, Limson G, Romanowski B, Aoki FY, Schwarz TF, PoppeWA, Bosch FX, Harper DM, Huh W, Hardt K, Zahaf T, Descamps D, Struyf F, Dubin G, Lehtinen M (2012) Cross-protective efficacy of HPV-16/18 AS04-Adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 13: 100-110.